ClinicalTrials.gg
WithdrawnNCT02968641LOWR-5Updated Feb 16, 2021

A Study of Lonafarnib With or Without Ritonavir in Patients With HDV

A Phase 2 interventional study of Lonafarnib and Ritonavir in Chronic Delta Hepatitis, sponsored by Eiger BioPharmaceuticals. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-16.

Sponsored by Eiger BioPharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was withdrawn
This study was initially planned to enroll patients in Mongolia. However, due to challenges in setting it up in Mongolia, this study was later determined not to be initiated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A Phase 2b, Open-Label, Randomized Study of the Safety, Tolerability, and Pharmacodynamic Activity of Lonafarnib With or Without Ritonavir in Patients Chronically Infected with Hepatitis Delta Virus

Read the detailed description

This Phase 2b, randomized, open-label study will assess the safety, tolerability, and pharmacodynamics (PD)/efficacy of 48 weeks of lonafarnib (LNF) and ritonavir (RTV) combination therapy vs. LNF monotherapy in patients with chronically infected with Hepatitis Delta Virus (CHD). Sixty patients will be enrolled at a single study site. Eligible patients will have CHD infection (≥ 6 months) confirmed by positive HDV antibody (Ab) test and HDV RNA ≥ 3 lg IU/mL by quantitative polymerase chain reaction (qPCR) at study entry.

02

Conditions studied

  • Chronic Delta Hepatitis

Browse trials for

03

In context

Hepatitis D, Chronic

43 studies on the registry are indexed under Hepatitis D, Chronic; 9 are open to participants now.

Browse Hepatitis D, Chronic studies →

Lead sponsor

Eiger BioPharmaceuticals is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Willing and able to comply with study procedures and provide written consent
  2. 18 - 65 years old
  3. (BMI) of ≥ 18 kg/m2 and weighs ≥ 45 kg
  4. CHD infection of at least 6 months' duration documented by a positive HDV antibody (Ab) test and HDV RNA ≥ 3 log10/mL by qPCR at study entry
  5. Serum > (ULN) and \< 10 × ULN
  6. Liver within 12 months of Day 1 demonstrating evidence of chronic hepatitis. If no liver biopsy is available, the patient must be willing to consent to and have no to liver biopsy
  7. ECGs demonstrating no acute ischemia or abnormality and a corrected for heart rate (QTcF) \< 450 ms for male patients and \< 460 ms for female patients
  8. Dilated retinal examination ≤ 1 year before screening: For patients with diabetes, hypertension, or other risk factors for retinal disease, performed by a licensed ocular specialist; for all other patients, a normal retinal examination as assessed by the investigator or a licensed ocular specialist
  9. Female patients of and male patients with partners of childbearing potential must agree to use adequate methods of during the study and for 90 days after the last dose of study drug. Female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year .

For females: 2 of the following contraceptive methods, with at least 1 being a barrier method:

  • Hormonal contraceptives for ≥ 3 months before screening
  • Intrauterine device (IUD) in place ≥ 3 months before screening
  • Double-barrier methods (use of condom [male partner] with either diaphragm with spermicide or cervical cap with spermicide) from screening
  • Surgical sterilization of the partner (vasectomy ≥ 1 month before screening)

For males:

  • Surgical sterilization (vasectomy ≥ 1 month before screening) or
  • Both of the following contraceptive methods from screening:

    • Consistently and correctly use a condom
    • Partner must agree to use a hormonal contraceptive or a nonhormonal barrier method (IUD or diaphragm with spermicide or cervical cap with spermicide)

Exclusion Criteria:

General Exclusions

  1. Participation in a clinical trial with, or use of, any agent within 30 days before screening
  2. Previous use of LNF.
  3. Female patients who are pregnant or breastfeeding. Male patients must confirm that their female sexual partners are not pregnant. Female patients must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [hCG]) within 24 hours prior to the start of any investigational agent).

    Exclusions Based on Disease

  4. Current or previous history of decompensated liver disease ( Class B or C)
  5. Co-infected with (HIV) or virus (HCV).
  6. Positive results for HIV or HCV Ab at screening. Patients with a positive HCV Ab at screening are allowed if they have completed a curative antiviral regimen and have documented undetectable HCV RNA for at least 3 months before screening and at screening.
  7. Past history or current evidence of decompensated liver disease, defined as any of the following at screening:

    • level ≥ 2.5 mg/dL unless due to Gilbert's disease
    • Serum albumin level \< 3.0 g/dL
    • (INR) ≥ 1.5
  8. Evidence of significant portal hypertension such as hepatic venous pressure gradient (HVPG) ≥ 10 mmHg; current presence or history of esophageal or abdominal varices, variceal bleeding, or splenomegaly > 12 cm length on imaging
  9. Current evidence or history of ascites requiring diuretics or paracentesis, or hepatic encephalopathy
  10. Current evidence or history of hepatic encephalopathy
  11. Any of the following abnormal laboratory test results at screening:

    • count \< 90,000 cells/mm3
    • White blood cell (WBC) count \< 3,000 cells/mm3
    • (ANC) \< 1,500 cells/mm3
      • \< 11 g/dL for women
      • \< 12 g/dL for men
    • Serum creatinine concentration ≥ 1.5 × ULN
    • Confirmed (CrCl) \< 50 mL/min by Cockroft-Gault or an estimated (eGFR) > 80 mL/min at screening, based on the Cockcroft-Gault equation
    • Alpha-fetoprotein ≥ 100 ng/mL
  12. Evidence of another form of viral hepatitis or another form of liver disease (eg, liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson's disease, alcoholic liver disease, nonalcoholic steatohepatitis, hemochromatosis, alpha-1-anti-trypsin deficiency)
  13. History of hepatocellular carcinoma
  14. Patients with any of the following:

    • Current eating disorder or alcohol abuse
    • Excessive alcohol intake, defined as follows:

      • > 20 g/day for females (1.5 standard alcohol drinks) or
      • > 30 g/day for males (2.0 standard alcohol drinks).
      • A standard drink contains 14 g of alcohol: 360 mL of beer, 150 mL of wine, or 45 mL of spirits
    • In the opinion of the investigator, an alcohol use pattern that will interfere with study conduct
    • Drug abuse within the previous 6 months before screening, with the exception of cannabinoids and their derivatives
  15. Prior history or current evidence of any of the following:

    • Immunologically mediated disease (eg, rheumatoid arthritis, inflammatory bowel disease, severe psoriasis, systemic lupus erythematosus) that requires more than intermittent nonsteroidal anti-inflammatory medications for management or that requires use of systemic in the 6 months before screening (inhaled asthma medications are allowed)
    • Retinal disorder or clinically relevant ophthalmic disorder
    • Any within 5 years before screening. Exceptions are superficial dermatologic malignancies (eg, squamous cell or basal cell skin cancer treated with curative intent), or successfully treated in-situ carcinoma of the cervix.
    • Cardiomyopathy or significant ischemic cardiac or cerebrovascular disease (including history of angina, myocardial infarction, or interventional procedure for coronary artery disease)
    • Chronic pulmonary disease (eg, ) associated with functional impairment
    • Pancreatitis
    • Severe or uncontrolled psychiatric disorder (eg, depression, manic condition, psychosis, acute and/or chronic cognitive dysfunction, suicidal behavior, and relapse of substance abuse)
    • Bone marrow or solid organ transplantation
  16. Other significant medical condition that may require intervention during the study. Patients with any serious condition that, in the opinion of the investigator, would preclude evaluation of response or make it unlikely that the contemplated course of therapy and follow-up could be completed. Patients for whom participation in the study would increase their risk.

    Exclusions Based on Concurrent Medication Use

  17. Any prescription or herbal product that is not approved by the investigator
  18. Therapy with an immunomodulatory agent, IFN-alfa (IFN alfa-2a or IFN alfa-2b, or pegylated IFN alfa-2a or alfa-2b), cytotoxic agent, or systemic corticosteroids within 12 months before screening and during the study
  19. Use of heparin or warfarin during the study
  20. Systemic antibiotics, antifungals, or antivirals for treatment of active infection other than within 14 days before study randomization or during the study
  21. Long-term treatment (> 2 weeks) before or during the study with agents that have a high risk for nephrotoxicity or hepatotoxicity unless it is approved by the medical monitor
  22. Receipt of systemic therapy within 3 months before screening or during the study
  23. History or evidence for any intolerance or to LNF, RTV, or other substances that are part of the study drug
  24. Concomitant use of any of the following:

    • Medications or foods that are known moderate or strong inducers or inhibitors of
    • Drugs known to prolong the PR or QT interval unless otherwise described in this protocol
    • Statins, due to inhibition of mevalonate synthesis, which reduces protein prenylation
  25. Concomitant use of medications contraindicated in the prescribing information for RTV
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    LNF 25 mg bid and RTV 100 mg bid

    Patients will take lonafarnib 25 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.

    Drug: Lonafarnib · Drug: Ritonavir

  • Active comparator
    LNF 50 mg bid and RTV 100 mg bid

    Patients will take lonafarnib 50 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.

    Drug: Lonafarnib · Drug: Ritonavir

  • Active comparator
    LNF 100 mg bid

    Patients will take lonafarnib 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.

    Drug: Lonafarnib

Interventions

  • antiviral farnesyltransferase inhibitor

    Also known as: EBP994, Sarasar

  • CYP 3A4 inhibitor, lonafarnib booster

    Also known as: Norvir

06

What researchers measure

Primary outcomes

  1. Change from baseline in HDV viral load at Week 72 visit (end of follow-up)

    HDV RNA viral load will be quantified with a real-time qPCR assay with a lower limit of quantification (LLOQ) of 14 IU/mL

    Time frame: 72 weeks

Secondary outcomes

  1. Change from baseline in HDV viral load at Week 48 visit (end of treatment, EOT)

    Time frame: 48 weeks

  2. Proportion of patients with histological response

    Histological response defined as an improvement in liver histology by at least 2 points in the Hepatitis Activity Score (HAI) with improvement or no worsening of the fibrosis score, at the EOT compared with baseline

    Time frame: 72 weeks

  3. Proportion of patients with sustained virologic response: HDV RNA below the LLOQ 12 weeks after EOT (48 weeks)

    Time frame: 60 weeks

  4. Proportion of patients with sustained virologic response: HDV RNA below the LLOQ 24 weeks after EOT (48 weeks)

    Time frame: 72 weeks

  5. Number of participants with treatment-emergent changes in clinical laboratory findings

    Time frame: 48 weeks

  6. Number of participants with treatment-emergent / treatment-related adverse events (AE) and serious adverse events

    Time frame: 48 weeks

  7. Number of participants with AE leading to early discontinuation of study treatment or dose reduction

    Time frame: 48 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015 Oct;15(10):1167-1174. doi: 10.1016/S1473-3099(15)00074-2. Epub 2015 Jul 16. PubMed 26189433 ↗
  • Yurdaydin C, et al. Optimizing the Prenylation Inhibitor Lonafarnib Using Ritonavir Boosting in Patients with Chronic Delta Hepatitis. EASL 2015, Abstract 0118.
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02968641
Lead sponsor
Eiger BioPharmaceuticals
Responsible party
Sponsor
First posted
Nov 18, 2016
Primary completion
Feb 12, 2021
Last update
Feb 16, 2021

Study contacts

Eduardo B Martins, MD, DPhil
study director · Eiger BioPharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ritonavir

Start the discussion